NCT03267225 (CLINDA-RIFAM) is a clinical trial in VA Drug Interaction, sponsored by Dr Valerie ZELLER.

Who is sponsoring NCT03267225?

NCT03267225 is sponsored by Dr Valerie ZELLER.

What condition does NCT03267225 study?

NCT03267225 studies VA Drug Interaction.

Is NCT03267225 still recruiting?

NCT03267225 is currently completed. Last updated 24 October 2022.

Last reviewed 2022-10-24 · How we verify

NCT03267225: CLINDA-RIFAM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Genetic Determinants of Clindamycin/Rifampin Interaction

Completed Last updated 24 October 2022

What this trial tests

trial in VA Drug Interaction in 84 participants. Completed in 15 April 2021.

Timeline

1 January 2016

Primary endpoint
15 April 2021

15 April 2021

Quick facts

Lead sponsor	Dr Valerie ZELLER
Status	Completed
Study type	OBSERVATIONAL
Enrollment	84
Start date	1 January 2016
Primary completion	15 April 2021
Estimated completion	15 April 2021
Sites	1 location across France

Conditions studied

VA Drug Interaction — all drugs for VA Drug Interaction →

Sponsor

Dr Valerie ZELLER

Who can join

18 and older, any sex, with VA Drug Interaction. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Genetic polymorphism of PXR, LXRalpha, CYP450 on clindamycin clearance with clindamycin/rifampin combination therapy
Time frame: 10 days after onset of clindamycin/rifampin combination therapy
Impact of PXR, LXRα, CYP 450 3A4/A5 polymorphism on clindamycin clearance after combination clindamycin-rifampin therapy will be analyzed by studying the association of these polymorphisms and clindamycin serum concentrations.

Sponsor's own description

Main objective- To study the influence of the polymorphisms of nuclear receptor proteins pregnane X receptor (PXR), Liver X receptor alpha (LXRα), and Cytochrome P450 (CYP450) on the clindamycin clearance during clindamycin/rifampin combination therapy. Secondary objectives To study the influence of these polymorphisms on clindamycin clearance, before combination therapy with rifampin (clindamycin monotherapy) To study the influence of these polymorphisms on CYP450 activity before combination therapy with rifampin (clindamycin monotherapy) To study the influence of these polymorphisms on the increase of CYP450 activity after clindamycin/rifampin combination therapy To study the difference between the expected and observed clindamycin serum concentrations after dosage adjustment, in patients with clindamycin dosage adjustment after combination therapy with rifampin

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03267225 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr Valerie ZELLER
Last refreshed: 24 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03267225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing